Loading
A phase 1/2 trial of HDP-101 in multiple myeloma, run by Heidelberg Pharma AG, now recruiting.
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT04879043 by Heidelberg Pharma AG, with 78 participants planned, started 2022-02-07 and due to reach its primary completion in 2028-03. Interventions recorded: HDP-101.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.